585 related articles for article (PubMed ID: 16768547)
1. The BARD1 Cys557Ser variant and breast cancer risk in Iceland.
Stacey SN; Sulem P; Johannsson OT; Helgason A; Gudmundsson J; Kostic JP; Kristjansson K; Jonsdottir T; Sigurdsson H; Hrafnkelsson J; Johannsson J; Sveinsson T; Myrdal G; Grimsson HN; Bergthorsson JT; Amundadottir LT; Gulcher JR; Thorsteinsdottir U; Kong A; Stefansson K
PLoS Med; 2006 Jul; 3(7):e217. PubMed ID: 16768547
[TBL] [Abstract][Full Text] [Related]
2. Nordic collaborative study of the BARD1 Cys557Ser allele in 3956 patients with cancer: enrichment in familial BRCA1/BRCA2 mutation-negative breast cancer but not in other malignancies.
Karppinen SM; Barkardottir RB; Backenhorn K; Sydenham T; Syrjäkoski K; Schleutker J; Ikonen T; Pylkäs K; Rapakko K; Erkko H; Johannesdottir G; Gerdes AM; Thomassen M; Agnarsson BA; Grip M; Kallioniemi A; Kere J; Aaltonen LA; Arason A; Møller P; Kruse TA; Borg A; Winqvist R
J Med Genet; 2006 Nov; 43(11):856-62. PubMed ID: 16825437
[TBL] [Abstract][Full Text] [Related]
3. BARD1 and breast cancer in Poland.
Jakubowska A; Cybulski C; Szymańska A; Huzarski T; Byrski T; Gronwald J; Debniak T; Górski B; Kowalska E; Narod SA; Lubiński J
Breast Cancer Res Treat; 2008 Jan; 107(1):119-22. PubMed ID: 17333333
[TBL] [Abstract][Full Text] [Related]
4. The BARD1 Cys557Ser variant and risk of familial breast cancer in a South-American population.
Gonzalez-Hormazabal P; Reyes JM; Blanco R; Bravo T; Carrera I; Peralta O; Gomez F; Waugh E; Margarit S; Ibañez G; Santos JL; Jara L
Mol Biol Rep; 2012 Aug; 39(8):8091-8. PubMed ID: 22544576
[TBL] [Abstract][Full Text] [Related]
5. Common genetic variation at BARD1 is not associated with breast cancer risk in BRCA1 or BRCA2 mutation carriers.
Spurdle AB; Marquart L; McGuffog L; Healey S; Sinilnikova O; Wan F; Chen X; Beesley J; Singer CF; Dressler AC; Gschwantler-Kaulich D; Blum JL; Tung N; Weitzel J; Lynch H; Garber J; Easton DF; Peock S; Cook M; Oliver CT; Frost D; Conroy D; Evans DG; Lalloo F; Eeles R; Izatt L; Davidson R; Chu C; Eccles D; Selkirk CG; Daly M; Isaacs C; Stoppa-Lyonnet D; Sinilnikova OM; Buecher B; Belotti M; Mazoyer S; Barjhoux L; Verny-Pierre C; Lasset C; Dreyfus H; Pujol P; Collonge-Rame MA; ; Rookus MA; Verhoef S; Kriege M; Hoogerbrugge N; Ausems MG; van Os TA; Wijnen J; Devilee P; Meijers-Heijboer HE; Blok MJ; Heikkinen T; Nevanlinna H; Jakubowska A; Lubinski J; Huzarski T; Byrski T; Durocher F; Couch FJ; Lindor NM; Wang X; Thomassen M; Domchek S; Nathanson K; Caligo M; Jernström H; Liljegren A; Ehrencrona H; Karlsson P; ; Ganz PA; Olopade OI; Tomlinson G; Neuhausen S; Antoniou AC; Chenevix-Trench G; Rebbeck TR
Cancer Epidemiol Biomarkers Prev; 2011 May; 20(5):1032-8. PubMed ID: 21393566
[TBL] [Abstract][Full Text] [Related]
6. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium.
Lancet; 1997 May; 349(9064):1505-10. PubMed ID: 9167459
[TBL] [Abstract][Full Text] [Related]
7. BARD1 variants Cys557Ser and Val507Met in breast cancer predisposition.
Vahteristo P; Syrjäkoski K; Heikkinen T; Eerola H; Aittomäki K; von Smitten K; Holli K; Blomqvist C; Kallioniemi OP; Nevanlinna H
Eur J Hum Genet; 2006 Feb; 14(2):167-72. PubMed ID: 16333312
[TBL] [Abstract][Full Text] [Related]
8. Mutations in the BRCA1-associated RING domain (BARD1) gene in primary breast, ovarian and uterine cancers.
Thai TH; Du F; Tsan JT; Jin Y; Phung A; Spillman MA; Massa HF; Muller CY; Ashfaq R; Mathis JM; Miller DS; Trask BJ; Baer R; Bowcock AM
Hum Mol Genet; 1998 Feb; 7(2):195-202. PubMed ID: 9425226
[TBL] [Abstract][Full Text] [Related]
9. The BARD1 Cys557Ser polymorphism and breast cancer risk: an Australian case-control and family analysis.
Johnatty SE; Beesley J; Chen X; Hopper JL; Southey MC; Giles GG; Goldgar DE; Chenevix-Trench G; Spurdle AB; ;
Breast Cancer Res Treat; 2009 May; 115(1):145-50. PubMed ID: 18481171
[TBL] [Abstract][Full Text] [Related]
10. Lack of association between BARD1 Cys557Ser variant and breast cancer risk: a meta-analysis of 11,870 cases and 7,687 controls.
Ding DP; Zhang Y; Ma WL; He XF; Wang W; Yu HL; Guo YB; Zheng WL
J Cancer Res Clin Oncol; 2011 Oct; 137(10):1463-8. PubMed ID: 21809034
[TBL] [Abstract][Full Text] [Related]
11. [Association between single nucleotide polymorphisms of BARD 1 gene and susceptibility of early-onset breast cancer in Uygur women in Xinjiang].
Sun G; Wang JT; Ma BL; Geng ZL; Ren GH; Shan MH; Ma B; Ma LL; Wang Y
Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):341-7. PubMed ID: 22883453
[TBL] [Abstract][Full Text] [Related]
12. Phenotypic analysis of familial breast cancer: comparison of BRCAx tumors with BRCA1-, BRCA2-carriers and non-familial breast cancer.
Aloraifi F; Alshehhi M; McDevitt T; Cody N; Meany M; O'Doherty A; Quinn CM; Green AJ; Bracken A; Geraghty JG
Eur J Surg Oncol; 2015 May; 41(5):641-6. PubMed ID: 25736863
[TBL] [Abstract][Full Text] [Related]
13. Population-based study of changing breast cancer risk in Icelandic BRCA2 mutation carriers, 1920-2000.
Tryggvadottir L; Sigvaldason H; Olafsdottir GH; Jonasson JG; Jonsson T; Tulinius H; Eyfjörd JE
J Natl Cancer Inst; 2006 Jan; 98(2):116-22. PubMed ID: 16418514
[TBL] [Abstract][Full Text] [Related]
14. Cancer predisposing missense and protein truncating BARD1 mutations in non-BRCA1 or BRCA2 breast cancer families.
De Brakeleer S; De Grève J; Loris R; Janin N; Lissens W; Sermijn E; Teugels E
Hum Mutat; 2010 Mar; 31(3):E1175-85. PubMed ID: 20077502
[TBL] [Abstract][Full Text] [Related]
15. Haplotype analysis in Icelandic and Finnish BRCA2 999del5 breast cancer families.
Barkardottir RB; Sarantaus L; Arason A; Vehmanen P; Bendahl PO; Kainu T; Syrjäkoski K; Krahe R; Huusko P; Pyrhönen S; Holli K; Kallioniemi OP; Egilsson V; Kere J; Nevanlinna H
Eur J Hum Genet; 2001 Oct; 9(10):773-9. PubMed ID: 11781689
[TBL] [Abstract][Full Text] [Related]
16. Histopathological features of breast cancer in carriers of ATM gene variants.
Balleine RL; Murali R; Bilous AM; Farshid G; Waring P; Provan P; Byth K; Thorne H; ; Kirk JA
Histopathology; 2006 Nov; 49(5):523-32. PubMed ID: 17064299
[TBL] [Abstract][Full Text] [Related]
17. A nonsense mutation (E1978X) in the ATM gene is associated with breast cancer.
Bogdanova N; Cybulski C; Bermisheva M; Datsyuk I; Yamini P; Hillemanns P; Antonenkova NN; Khusnutdinova E; Lubinski J; Dörk T
Breast Cancer Res Treat; 2009 Nov; 118(1):207-11. PubMed ID: 18807267
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population.
Meindl A;
Int J Cancer; 2002 Feb; 97(4):472-80. PubMed ID: 11802209
[TBL] [Abstract][Full Text] [Related]
19. Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers.
Adem C; Reynolds C; Soderberg CL; Slezak JM; McDonnell SK; Sebo TJ; Schaid DJ; Myers JL; Sellers TA; Hartmann LC; Jenkins RB
Cancer; 2003 Jan; 97(1):1-11. PubMed ID: 12491499
[TBL] [Abstract][Full Text] [Related]
20. Haplotype analysis suggest common founders in carriers of the recurrent BRCA2 mutation, 3398delAAAAG, in French Canadian hereditary breast and/ovarian cancer families.
Oros KK; Leblanc G; Arcand SL; Shen Z; Perret C; Mes-Masson AM; Foulkes WD; Ghadirian P; Provencher D; Tonin PN
BMC Med Genet; 2006 Mar; 7():23. PubMed ID: 16539696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
